Page 3 - கார்டிஃப் புற்றுநோயியல் இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cardiff Oncology in Collaboration with MIT Presents Gene Signature Analyses Data Identifying Androgen-Independent Mechanism for Onvansertib-Abiraterone Synergy in mCRPC

Share this article SAN DIEGO, April 10, 2021 /PRNewswire/ Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer and castrate-resistant prostate cancer, in collaboration with scientists in the Center for Precision Cancer Medicine at the Massachusetts Institute of Technology (MIT), today announced that new gene signature and mechanistic analyses related to its ongoing Phase 2 trial of onvansertib in metastatic castrate-resistant prostate cancer (mCRPC) were featured in a virtual oral poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021.

Dana farber cancer instituteUnited statesMassachusetts institute of technologyDavidh kochMichaelb yaffeDavid einsteinKatelyn caruso sharpeMark erlanderVicki kelemenJoyce allaireCardiff oncology incHospital cancer centerBeth israel deaconess medical centerPrnewswire cardiff oncology incExchange commissionGenitourinary oncology program

Cardiff Oncology Presents Findings from its Expanded Access Program Highlighting the Clinical Benefit of Onvansertib in Heavily Pretreated Patients with Metastatic KRAS-Mutated mCRC

Cardiff Oncology Presents Findings from its Expanded Access Program Highlighting the Clinical Benefit of Onvansertib in Heavily Pretreated Patients with Metastatic KRAS-Mutated mCRC
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Katelyn caruso sharpeMark erlanderVicki kelemenJoyce allaireManishr sharmaExchange commissionCardiff oncology incLifesci communicationsAccess programCardiff oncologyExpanded access programEvaluable patientsColorectal cancerPolo like kinasePrivate securities litigation reform actOncology contact

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ACHL) - The Week Ahead In Biotech: Regeneron, Supernus FDA Decisions, Cancer Conference Presentations In The Spotlight

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ACHL) - The Week Ahead In Biotech: Regeneron, Supernus FDA Decisions, Cancer Conference Presentations In The Spotlight
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

United statesEli lillyOncolytics biotech incTeos therapeutics incCodiak biosciences incZentalis pharmaceuticals incSupernus pharmaceuticals incGreenwich lifesciences incIovance biotherapeutics incGlycomimetics incTherapeutics incPfizer incHumanigen incPieris pharmaceuticals incCardiff oncology incRegeneron pharmaceuticals inc

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2021

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2021 News provided by Share this article SAN DIEGO, March 10, 2021 /PRNewswire/ Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer, castrate-resistant prostate cancer and leukemias, today announced the publication of two abstracts that will be presented as electronic posters during Week 1 of the American Association for Cancer Research (AACR) Annual Meeting 2021, taking place virtually from April 10-15, 2021. Details on the electronic posters and corresponding abstracts are shown below. Title: Expanded access program of the PLK1 inhibitor onvansertib for treatment of patients with KRAS-mutant metastatic colorectal cancer

United statesDana farber cancer instituteDavid einsteinKatelyn caruso sharpeVicki kelemenJoyce allaireClinical outcomes researchCardiff oncology incHospital cancer centerBeth israel deaconess medical centerPrnewswire cardiff oncology incCardiff oncology expanded access programClinical research excluding trialsGenitourinary oncology programAmerican association for cancer researchLifesci communications

Cardiff Oncology to Present at H C Wainwright Global Life Sciences Conference

Share this article SAN DIEGO, March 3, 2021 /PRNewswire/ Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer, castrate-resistant prostate cancer and leukemias, today announced that the Company will present at the upcoming H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021. The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. ET on Tuesday, March 9, 2021. The Company will also participate in one-on-one meetings with investors during the conference. About Cardiff Oncology, Inc.

Karen osheaVicki kelemenJoyce allaireCardiff oncology incLifesci communicationsHc wainwright global life sciences conferencePrnewswire cardiff oncology incGlobal life sciences conferenceCardiff oncologyPolo like kinaseOncology contactகரேன் ஓஷேஆமகிழ்ச்சி அல்லேர்கார்டிஃப் புற்றுநோயியல் இன்க்ஹ்ஸீ வேந்‌ரைட் உலகளாவிய வாழ்க்கை அறிவியல் மாநாடுஉலகளாவிய வாழ்க்கை அறிவியல் மாநாடு